Education
About Us
Working with TipRanks
Follow Us
Precipio Inc (PRPO)
NASDAQ:PRPO
PRPO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.90 - $16.89
Previous CloseN/A
Volume11.00
Average Volume (3M)14.47K
Market Cap
$21.94M
Enterprise Value$23.49M
Total Cash (Recent Filing)$1.02M
Total Debt (Recent Filing)$2.16M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,512,011
10 Day Avg. Volume24,888
30 Day Avg. Volume14,471
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.86
Price to Sales (P/S)0.00
P/FCF Ratio31.28
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue0.33
Enterprise Value/Gross Profit2.77
Enterprise Value/Ebitda-2.80
Forecast
1Y Price Target
$11.50Price Target Upside-20.74% Downside
Rating ConsensusHold
Number of Analyst Covering0
Precipio News
PremiumCompany Announcements
Precipio Holds Annual Stockholders Meeting, Approves Proposals
PremiumCompany Announcements
Precipio’s Earnings Call: Cautious Optimism Amid Growth
PremiumCompany Announcements
Precipio Reports Strong Q1-2025 Revenue Growth
PremiumCompany Announcements
Precipio Schedules Q1-2025 Shareholder Update Call
PremiumCompany Announcements
Precipio’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Precipio Reports Positive Q4 Financial ResultsOptions Prices
Currently, No data available
---
Ownership Overview
12.86% Insiders
2.07% Mutual Funds
2.53% Other Institutional Investors
81.37% Public Companies and
Individual Investors
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $3.90 and its highest was $16.89 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $21.94M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Aug 25, 2025 which is in 34 days.
How were Precipio Inc’s earnings last quarter?
Currently, no data Available
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,512,011 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
Company Description
Precipio Inc
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
PRPO Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong year-over-year revenue growth, improved margins, and significant operational efficiency gains. However, these positives were somewhat offset by a quarter-over-quarter revenue decline, delays in product division revenue realization, and initial uncertainty regarding FDA regulations. Despite these challenges, the overall sentiment remains cautiously optimistic, with expectations of continued growth and positive cash flow in the coming quarters.Read More>Technical Analysis
Neurometrix
―
Eterna Therapeutics
―
Kiora Pharmaceuticals
―
Lyra Therapeutics
―
Acurx Pharmaceuticals
―